dyvic2: Dynamic Variation of Impedance Cardiography(DYVIC) as a Diagnostic Tool of Acute Heart Failure (AHF)

Sponsor
University of Monastir (Other)
Overall Status
Completed
CT.gov ID
NCT04484298
Collaborator
(none)
100
1
2
13.9
7.2

Study Details

Study Description

Brief Summary

the study aimed to evaluate the diagnostic performance of cardiac output (CO) change after the use of trinitrine in the diagnosis of heart failure patients with acute dyspnea.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Reference position patient is put in a 30 degree supine position during 5 minutes
  • Diagnostic Test: nitroglucerin
N/A

Detailed Description

Acute heart failure (AHF) is a frequent condition in emergency department and is responsible of high number of admissions, complications, and deaths.

despite advances in diagnostic techniques, AHF diagnosis still be challenging .

Measurement of cardiac output (CO) is used to evaluate global cardiac function and changes in CO may be used to identify a change in the hemodynamic status of patient.

the gold standard of measuring CO is thermodilution catheterization, however it is an invasive technique with high risks.

Impedance cardiography (ICG) is a noninvasive method for measuring CO. it is performed by applying small electrical current to the chest through electrodes placed on the neck and sides.

the pulsatile flow of blood causes fluctuations in the current, and the device calculates CO from the impedance waveform.

In practice, the investigators connect the device "BIOPAC" by using four electrodes which the investigators place on the base of the neck (posterior face) and on the base of the thorax (posterior face).

The ECG recording is taken simultaneously with two other electrodes placed at the right upper limb and left lower limb.

In addition to detecting the electric current and the ECG, heart sounds are recorded using a sensor that is placed at the mitral site.

Each patient is initially placed in a semi-sitting position at 30° for 5 minutes and then CO is measured (baseline CO). NTG (0.6 mg) is then given to the patient sublingually and CO measurement was repeated. CO is calculated by averaging three measurements at one minute intervals at baseline and after NTG administration. DeltaCO was defined as the percent of change of baseline CO after NTG test.

Study Design

Study Type:
Interventional
Actual Enrollment :
100 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Masking:
Triple (Participant, Care Provider, Outcomes Assessor)
Primary Purpose:
Diagnostic
Official Title:
Dynamic Variation of Impedance Cardiography (ICG) a Diagnostic Tool of Acute Heart Failure (AHF) in Emergency Department (ED) Patients Admitted for Acute Dyspnea
Actual Study Start Date :
Jan 2, 2019
Actual Primary Completion Date :
Feb 29, 2020
Actual Study Completion Date :
Mar 1, 2020

Arms and Interventions

Arm Intervention/Treatment
Experimental: reference group

patients presenting to the emergency department with acute onset dyspnea are assessed for acute heart failure using the bio impedance technology (BIOPAC system) to measure the cardiac output in different clinical situations. FIRST: the cardiac output (CO) is measured at the reference position. Inbetween each step the patient was put in the reference position during 5 minutes.

Diagnostic Test: Reference position patient is put in a 30 degree supine position during 5 minutes
Each patient is initially placed in a semi-sitting position at 30° for 5 minutes and then CO is measured (baseline CO)

Experimental: TRINITRINE

0.6 mg of nitroglycerin was given to the patient sublingual and we measure the cardiac output by BIOPAC system(0.6 mg of Nitroglycerin was administered sublingually and CO was evaluated.

Diagnostic Test: nitroglucerin
0.6 mg of Nitroglycerin was administered by sublingual root and CO was evaluated.

Outcome Measures

Primary Outcome Measures

  1. Cardiac output variation measured by ICG before and after nitroglycerin in acute dyspneic patients between the AHF and non AHF groups [24 hours]

    the diagnostic performance is evaluated by calculating the CO in ml/min by bio-impedance technique and compare the values between patients with and without AHF and between baseline.

  2. roc curve [24]

    Receiver operating characteristic (ROC) curves for predicting HF were constructed and area under curve (AUC) was measured for the deltaCO.

  3. Sensitivity, specificity, positive and negative predictive values, and likelihood ratios of positive and negative results were calculated using the optimal cutoff value of deltaCO. [24 hours]

    Sensitivity, specificity, positive and negative predictive values, and likelihood ratios of positive and negative results were calculated using the optimal cutoff value of deltaCO.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • 18 year old or above non traumatic acute dyspnea
Exclusion Criteria:
  • ECG diagnostic for acute myocardial infarction or ischemic chest pain within the prior 24 hours,

  • pericardial effusion ,

  • chest wall deformity suspected of causing dyspnea,

  • coma,

  • need for mechanical ventilation or vasopressor drugs,

  • serious and sustained arrhythmia,

  • pace maker,

  • severe mitral valve disease, severe pulmonary arterial hypertension,

  • renal failure (creatinine >350µmol/l.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Emergency department of fattouma bourguiba university hospital Monastir Tunisia 5020

Sponsors and Collaborators

  • University of Monastir

Investigators

  • Principal Investigator: nouira semir, MD, University of Monastir

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Pr. Semir Nouira, professor semir nouira, University of Monastir
ClinicalTrials.gov Identifier:
NCT04484298
Other Study ID Numbers:
  • DYVIC2
First Posted:
Jul 23, 2020
Last Update Posted:
Mar 29, 2021
Last Verified:
Mar 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Pr. Semir Nouira, professor semir nouira, University of Monastir
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 29, 2021